RTP Mobile Logo

Friday, December 6, 2019, Orlando, Florida, 12:30 PM – 3:30 PM

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

A Friday Satellite Symposium Preceding the 61st ASH Annual Meeting

This activity, the first of a 2-part series, will focus on common practical issues and challenges faced by clinicians caring for patients with lymphoma and chronic lymphocytic leukemia. Six world-renowned investigators will serve as the faculty. Leading up to the event, Research To Practice will recruit community-based medical and hematologic oncologists to participate in a unique assessment to identify specific challenging clinical situations or questions they have related to the management of these diseases for which they would seek investigator input. The live event will be divided into 6 distinct topic modules, each featuring a discussion of the questions and issues presented by the consulting clinicians and a faculty member-led review of relevant ongoing research. To cultivate a more interactive experience, clinicians in attendance will utilize networked iPads® to complete an onsite survey featuring a number of the same questions and topics to be discussed, the results of which will be presented and discussed throughout the program.

Event Details

Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

12:30 PM – 1:00 PM — Registration and Lunch Buffet
1:00 PM – 3:30 PM — Educational Meeting

Meeting Room
Orange Ballroom (Lower Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bruce D Cheson, MD
Frank M Ewing Foundation Chair in
Professor of Medicine
Head of Hematology and Cellular Therapy
Deputy Chief, Division of Hematology-Oncology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Prof John G Gribben, MD, DSc, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
London, United Kingdom

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Loretta Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Associate Editor, Blood
Vancouver, Canada

Neil Love, MD
Research To Practice
Miami, Florida


Event Time
12:30 PM – 1:00 PM — Registration and Lunch Buffet
1:00 PM – 3:30 PM — Educational Meeting

MODULE 1: Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)

  • Clinical implications of the Phase III ECOG-ACRIN E1912 trial comparing ibrutinib/rituximab to FCR (fludarabine/cyclophosphamide/rituximab) for young, fit patients with treatment-naïve CLL
  • Key efficacy findings from the Phase III Alliance A041202 trial evaluating ibrutinib versus ibrutinib/rituximab versus bendamustine/rituximab (BR) for older patients with CLL
  • Available data with and FDA approval of ibrutinib/obinutuzumab for treatment-naïve CLL
  • Emerging results from the CLL14 trial comparing obinutuzumab/venetoclax to obinutuzumab/chlorambucil for patients with newly diagnosed CLL and coexisting medical conditions

MODULE 2: Currently Available and Novel Investigational Approaches for Patients with Relapsed/Refractory (R/R) CLL

  • Long-term follow-up data from the Phase III MURANO trial comparing venetoclax/rituximab to BR for patients with R/R disease
  • Practical integration of venetoclax into the care of patients with R/R CLL
  • Published efficacy and safety experience with and ongoing evaluation of acalabrutinib for patients with R/R CLL
  • Early activity and safety data with and ongoing Phase III trials evaluating novel combination strategies

MODULE 3: Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)

  • Results of the Phase III RELEVANCE trial evaluating the “R-squared” regimen of lenalidomide/rituximab for newly diagnosed FL
  • Clinical and research implications of the Phase III AUGMENT trial comparing R-squared to rituximab monotherapy for R/R indolent lymphomas
  • Current clinical roles of obinutuzumab-based induction and maintenance therapy for previously untreated FL
  • Mechanistic similarities and differences among commercially available PI3 kinase inhibitors; research database supporting the FDA approvals of copanlisib and duvelisib in R/R FL

MODULE 4: Protocol and Nonresearch Care of Patients with Mantle Cell Lymphoma (MCL)

  • Early activity and safety data associated with ibrutinib alone or in combination with other systemic therapies for patients with previously untreated MCL
  • Mechanistic and pharmacodynamic similarities and differences between ibrutinib and acalabrutinib; clinical research data supporting the FDA approval of acalabrutinib for R/R MCL
  • Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in the treatment of R/R MCL
  • Other promising agents and strategies under investigation in the front-line and R/R settings

MODULE 5: Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

  • Available and emerging research information with lenalidomide for newly diagnosed and R/R DLBCL
  • Role and frequency of CD79b protein overexpression in DLBCL; components and mechanism of action of the antibody-drug conjugate polatuzumab vedotin
  • Primary and secondary endpoints achieved in the Phase II trial comparing polatuzumab vedotin and BR to BR alone for R/R DLBCL; FDA breakthrough therapy designation and ongoing Phase III evaluation
  • Other novel agents and strategies under investigation in DLBCL

MODULE 6: Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphoma

  • Compositional and mechanistic similarities and differences between available and investigational CD19-directed CAR-T platforms
  • Available efficacy and safety data with various CAR-T constructs in patients with aggressive lymphomas
  • Patient identification and appropriate referral for consideration of CAR T-cell therapy
  • Ongoing evaluation of CD19-directed CAR T-cell therapy in CLL and other lymphoma variants

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and CLL, and use this information to counsel patients regarding protocol and off-protocol therapy.
  • Consider published Phase III efficacy and safety data evaluating the use of BTK (Bruton tyrosine kinase) inhibition as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recall the biologic rationale for, available research evidence with and ongoing research efforts evaluating the use of chemotherapy-free combinations for newly diagnosed and progressive FL, CLL and MCL to prepare for their potential introduction into the practical management of these diseases.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor (CAR) T-cell therapy, and identify patients with relapsed/refractory B-cell cancers for whom this approach may be appropriate.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, FL and CLL, and where applicable, refer eligible patients for trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.


Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Meeting Room
Orange Ballroom (Lower Level)

The Hilton Orlando hotel is conveniently located within walking distance of the Orange County Convention Center, where the ASH Annual Meeting is taking place.



This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.